Takeaways: Roche’s pCPA win for Itovebi is a major reimbursement de-risking event in Canada, because it moves the drug much closer to broad public coverage after a ...
Takeaways: Heidi’s native Accuro EMR integration gives it instant scale across Canada’s largest clinician EMR (25,000+ users), making it more sticky and defensible while enab...
Takeaways: Kye Pharmaceuticals’ launch of Dyanavel XR in Canada adds a first-and-only chewable/swallowable extended-release amphetamine for ADHD in adults and children 6–12 years, alig...
Takeaways MedExpress is adding another low-cost telehealth channel for generic semaglutide in Canada, which should increase competition among virtual clinics and make GLP‑1 access even easier fo...
Takeaways Optimi is using its Nasdaq uplist and 1‑for‑30 share consolidation to raise roughly 15 million US dollars at scale, then plow the cash into making and selling ...
Takeaways Blenrep’s pCPA negotiations are an important step toward broader Canadian access to a new multiple myeloma option, especially because the drug is being positio...
Takeaways Orimed’s expanded PrLuxa‑D line should make vitamin D supplementation more flexible in Canada by covering a much wider dose range, which helps physicians match treatment to defici...
Takeaways Novartis is using this initiative to deepen its positioning as a “health equity partner” to government and community groups in Canada, with a fresher focus on women and gender‑diverse ...
Takeaways Dr. Reddy’s is using this Canada launch to cement itself as an early global player in generic GLP‑1 injectables, showing it can move from approval to market in days and supply at ...
Takeaways: Felix is positioning itself as the price‑breaker in Canada’s GLP‑1 obesity market, using cheaper semaglutide (as generics arrive) to tackle the main dropout driver and convert strong ...
